FindTrial
Sign In

Impact of Dapagliflozin on Brain Health in People with Uncontrolled Type 2 Diabetes

Effect Of Dapagliflozin On Serum Brain-Derived Neurotrophic Factor (BDNF) Levels In Uncontrolled Type 2 Diabetes Mellitus Patients- A Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/090876
Enrollment
80
Registered
2025-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Prasanjit Das
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Uncontrolled T2DM patients aged more than or equal to 18 years with standard antidiabetic treatment [Metformin with any of the Dipeptidyl peptidase 4 inhibitor (DPP4i)] who are started on Dapagliflozin or a Sulfonylurea (SU) group of drugs like Glimepiride for DM control

Exclusion criteria

Exclusion criteria: a) Type 1 diabetes mellitus (T1DM) patients. b) T2DM patients on Basal Insulin + Metformin + Another Oral Antidiabetic drug or patients on triple Oral Antidiabetic drug combination at the time of recruitment.

Design outcomes

Primary

MeasureTime frame
Serum BDNF levelsTimepoint: At the time of recruitment and at 3 months—

Secondary

MeasureTime frame
FBS, PPBS, HbA1c and PHQ-9 ScoresTimepoint: At the time of recruitment and at 3 months—

Countries

India

Contacts

Public ContactPrasanjit Das

All India Institute of Medical Sciences, Kalyani

karunasree.pharma@aiimskalyani.edu.in9494554545

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026